Chemours Co (CC) · Nov 2, 2026 · Earnings

Chemours earnings miss as TSS slump offsets TiO2, AI gains

Miss — Adjusted EPS $0.21 vs ~$0.27 consensus

Chemours earnings show pricing and AI-linked APM growth, but a sharp TSS downturn drives an adjusted EPS miss and lower full-year EBITDA ceiling.

Chemours is trying to shift its earnings mix toward TiO2 pricing power and higher-value APM products tied to data centers and semiconductors, while absorbing weaker refrigerant aftermarket demand and legacy PFAS costs. That setup was already visible before this report: second-quarter guidance explicitly called for TSS weakness, stronger APM demand, and full-year Adjusted EBITDA of $775 million to $825 million.

The quarter missed the clean earnings benchmark. Adjusted EPS was $0.21 versus published consensus of roughly $0.26-$0.27, while revenue of $1.54 billion was only modestly above the roughly $1.53 billion expectation. The headline $1.29 GAAP EPS is inflated by a $150 million PFAS insurance receipt, so the adjusted result is the better measure of ongoing performance. 〔0〕

MetricQ3 2026Q3 2025Consensus / prior guide
Net sales (Financial Highlights)$1,540M (+3%)$1,495M~$1,530M
Adjusted EPS (Financial Highlights)$0.21 (+24%)$0.17~$0.27
Adjusted EBITDA (Financial Highlights)$200M (+6%)$189M$175M-$205M Q3 guide
TSS Adjusted EBITDA (Segment results — TSS)$136M (-30%)$194M$125M-$140M Q2 guide
TT Adjusted EBITDA (Segment results — TT)$85M (+240%)$25M—
APM Adjusted EBITDA (Segment results — APM)$24M (+71%)$14M—
FY2026 Adjusted EBITDA outlook (Full Year 2026 Outlook)$775M-$800M—$775M-$825M

TT is executing, but not enough to carry the portfolio alone. Titanium Technologies produced 11% sales growth and lifted Adjusted EBITDA to $85 million from $25 million, powered by a 10% price increase and slightly higher volumes. APM also supports the intended mix shift: Performance Solutions sales rose 26% on order strength in data centers and semiconductors, although total APM EBITDA remains small at $24 million. 〔1〕

TSS remains the decisive weakness. TSS sales fell 9%, Opteon refrigerant sales dropped 22%, and segment EBITDA declined 30% with margin down eight points to 27%. The company had already warned that the 2025 channel-fill comparison would fade, so the direction was known; the deterioration still leaves the legacy profit base under pressure.

Management lowered the quality of the full-year outlook. The FY2026 EBITDA range was narrowed from $775 million-$825 million to $775 million-$800 million, while the year-end net-leverage target moved from around 3.8x to below 4.2x. The lower capex plan helps cash preservation, but the revised leverage ambition signals that the balance-sheet repair is progressing more slowly than previously expected. The company also says Q4 sales will fall 5%-10% sequentially as TSS and TT enter seasonal weakness, partly offset by a low-to-mid-teens APM sales increase.

Bottom line: Pricing and AI-linked APM demand are validating the strategic direction, but they are not yet large enough to offset the TSS earnings hole. The adjusted EPS miss and lower full-year EBITDA ceiling make this a modest setback rather than a reset of the broader story.

What to watch next

Q3 earnings call, November 3

Original filing on SEC EDGAR

More Chemours Co news

Chemours earnings miss as TSS slump offsets TiO2, AI gains | CC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.